Fixed Duration News Today

Fixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lymphoma, according to updated data from the phase 2 GO29781 trial.

Although minimal residual disease (MRD) has emerged as a valuable prognostic marker across several hematological malignancies, its use in chronic lymphocytic leukemia (CLL) is mostly limited to clinical trials.

With an abundance of targeted therapies transforming the treatment landscape for chronic lymphocytic leukemia, picking the optimal drug or regimen for the right situation can be a challenge.